Non-alcoholic Steatohepatitis Treatment Market Share

  • Report ID: 4695
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

 


Non-alcoholic Steatohepatitis Treatment Market Share

North American Market Forecast

The non-alcoholic steatohepatitis treatment market in the North American region is projected to hold the largest market share of 40% by the end of 2037. The growth of the market can be attributed majorly to the rising cases of non-alcoholic fatty liver diseases. Around 80 million to 100 million Americans are affected by non-alcoholic fatty liver disease. It has become the leading cause for liver transplant, surpassing hepatitis C. Moreover, out of total people suffering with NAFLD, around 30 million are affected by specifically non-alcoholic steatohepatitis (NASH). Additionally, the rising expenditure on the treatment of NASH patients is expected to boost the market growth in North America. The annual healthcare expense for NASH in the United States is around USD 5 billion. The expenditure entails various facilities, including testing, treatment, transplants, and hospitalization.

European Market Statistics

The non-alcoholic steatohepatitis treatment market in the Europe region is projected to hold the second largest share during the forecast period. The segment is expected to grow at a CAGR of 18.6% over the forecast period. Moreover, the market in Europe generated a revenue of USD 1,485.7 million in 2022. The market growth in the region is credited to the rise in the size of the obese population. According to the WHO European Regional Obesity Report 2022, 59% of adults and roughly one in three children (29% of boys and 27% of girls) in the region are overweight or obese.

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4695
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of non-alcoholic steatohepatitis treatment is estimated at USD 7.07 billion.

The non-alcoholic steatohepatitis treatment market size was valued at USD 6.16 billion in 2024 and is expected to cross USD 50.5 billion by the end of 2037, expanding at more than 18.2% CAGR during the forecast period i.e., between 2025-2037. Increasing incidences of NAFLD will drive the market growth.

North America industry is projected to hold the largest revenue share of 40% by 2037, backed by rising cases of non-alcoholic fatty liver diseases in the region.

The major players in the market include Intercept Pharmaceuticals, Inc., Pfizer, Inc., Inventiva, Galmed Pharmaceuticals Ltd., Novo Nordisk A/S, Madrigal Pharmaceuticals, Galectin Therapeutics, NGM Biopharmaceuticals, Brsitol-Myers Squibb Company, Can Fite, Zydus Lifesciences Ltd., Mitsubishi Chemical Group Corporation.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample